EA201300550A1 - Фармацевтическая композиция, способы лечения и их применение - Google Patents
Фармацевтическая композиция, способы лечения и их применениеInfo
- Publication number
- EA201300550A1 EA201300550A1 EA201300550A EA201300550A EA201300550A1 EA 201300550 A1 EA201300550 A1 EA 201300550A1 EA 201300550 A EA201300550 A EA 201300550A EA 201300550 A EA201300550 A EA 201300550A EA 201300550 A1 EA201300550 A1 EA 201300550A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- methods
- pharmaceutical composition
- treatment
- application
- preventing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Настоящее изобретение относится к фармацевтической композиции, включающей ингибитор SGLT2 и инсулин, которая пригодна для лечения или профилактики одного или более состояний, выбранных из группы, включающей сахарный диабет типа 1, сахарный диабет типа 2, нарушенную толерантность к глюкозе и гипергликемию. Настоящее изобретение также относится к способам профилактики или лечения метаболических нарушений и родственных состояний.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10190303 | 2010-11-08 | ||
EP11151059 | 2011-01-17 | ||
PCT/EP2011/069532 WO2012062698A1 (en) | 2010-11-08 | 2011-11-07 | Pharmaceutical composition, methods for treating and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201300550A1 true EA201300550A1 (ru) | 2014-02-28 |
EA026712B1 EA026712B1 (ru) | 2017-05-31 |
Family
ID=44906182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201300550A EA026712B1 (ru) | 2010-11-08 | 2011-11-07 | Применение ингибитора sglt2 |
Country Status (22)
Country | Link |
---|---|
US (5) | US20120283169A1 (ru) |
EP (2) | EP2637648A1 (ru) |
JP (3) | JP2013541576A (ru) |
KR (3) | KR20130125365A (ru) |
CN (2) | CN103282030A (ru) |
AP (1) | AP2013006813A0 (ru) |
AR (1) | AR083787A1 (ru) |
AU (1) | AU2011328231B2 (ru) |
BR (1) | BR112013011968A2 (ru) |
CA (1) | CA2813661C (ru) |
CL (1) | CL2013001104A1 (ru) |
CO (1) | CO6781465A2 (ru) |
EA (1) | EA026712B1 (ru) |
EC (1) | ECSP13012661A (ru) |
IL (1) | IL225597A0 (ru) |
MA (1) | MA34640B1 (ru) |
MX (1) | MX356491B (ru) |
NZ (1) | NZ608829A (ru) |
PE (1) | PE20140244A1 (ru) |
PH (1) | PH12018500767A1 (ru) |
SG (1) | SG189249A1 (ru) |
WO (1) | WO2012062698A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
NZ594487A (en) | 2009-02-13 | 2013-11-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
IN2012DN02751A (ru) | 2009-09-30 | 2015-09-18 | Boehringer Ingelheim Int | |
WO2011039107A1 (en) | 2009-09-30 | 2011-04-07 | Boehringer Ingelheim International Gmbh | Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene |
US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
US9192617B2 (en) | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
EP4245765A3 (en) | 2013-04-04 | 2024-03-20 | Boehringer Ingelheim Vetmedica GmbH | Treatment of metabolic disorders in equine animals |
US20140303098A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CA2812016A1 (en) | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
ES2906115T3 (es) | 2013-04-18 | 2022-04-13 | Boehringer Ingelheim Int | Composición farmacéutica, métodos de tratamiento y usos de la misma |
BR112016011564B1 (pt) * | 2013-12-17 | 2021-02-09 | Boehringer Ingelheim Vetmedica Gmbh | usos de inibidores de sglt2 ou formas farmaceuticamente aceitáveis dos mesmos para o tratamento de distúrbios metabólicos em animais felinos |
EP4234012A3 (en) * | 2014-01-23 | 2023-09-20 | Boehringer Ingelheim Vetmedica GmbH | Sglt2 inhibitors for treatment of metabolic disorders in canine animals |
MX2016012705A (es) * | 2014-04-01 | 2016-12-16 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabolicos en animales equinos. |
CA2956257C (en) | 2014-09-25 | 2022-07-12 | Boehringer Ingelheim Vetmedica Gmbh | Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals |
CN104473920A (zh) * | 2014-12-20 | 2015-04-01 | 长沙佰顺生物科技有限公司 | 一种用于治疗2型糖尿病的复方制剂及其制备方法 |
EP3341024A1 (en) | 2015-08-27 | 2018-07-04 | Boehringer Ingelheim Vetmedica GmbH | Liquid pharmaceutical compositions comprising sglt-2 inhibitors |
CN110092768A (zh) * | 2018-04-23 | 2019-08-06 | 中国科学院成都生物研究所 | 包含钠-葡萄糖协同转运蛋白1抑制剂的组合物及使用方法 |
CN110327355B (zh) * | 2019-08-12 | 2021-06-04 | 浙江养生堂天然药物研究所有限公司 | 包含柠檬苦素类化合物和sglt-2抑制剂的组合产品 |
US20220323400A1 (en) * | 2019-09-04 | 2022-10-13 | The Regents Of The University Of Michigan | Inhibitors of sglt and uses thereof |
US20210093698A1 (en) * | 2019-09-13 | 2021-04-01 | Sanofi | Treatment of type 2 diabetes mellitus |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ517439A (en) | 1999-08-31 | 2003-03-28 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof |
US6515117B2 (en) | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
PH12000002657B1 (en) | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
WO2002044192A1 (fr) | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Derives de glucopyranosyloxybenzylbenzene, compositions medicinales contenant ces derives et produits intermediaires obtenus lors de l'elaboration de ces compositions |
NZ526715A (en) | 2000-12-28 | 2005-02-25 | Kissei Pharmaceutical | Glucopyranosyloxypyrazole derivatives and use thereof in medicines |
PL210710B1 (pl) | 2002-03-22 | 2012-02-29 | Kissei Pharmaceutical | Krystaliczne postaci 2-(4-metoksybenzylo) fenylo-6-O-etoksykarbonylo-ß-D-glukopiranozydu, ich zastosowanie oraz zawierająca je kompozycja farmaceutyczna |
DE10231370B4 (de) | 2002-07-11 | 2006-04-06 | Sanofi-Aventis Deutschland Gmbh | Thiophenglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
WO2004080990A1 (ja) | 2003-03-14 | 2004-09-23 | Astellas Pharma Inc. | C-グリコシド誘導体又はその塩 |
PT2896397T (pt) | 2003-08-01 | 2017-11-23 | Mitsubishi Tanabe Pharma Corp | Novos compostos que possuem actividade inibidora dirigida contra transportadores de glucose dependentes do sódio |
DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
EP2295422A3 (de) | 2004-03-16 | 2012-01-04 | Boehringer Ingelheim International GmbH | Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
JP2008524162A (ja) | 2004-12-16 | 2008-07-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換ベンゼン誘導体、該化合物を含む薬物、その使用及びその製造方法 |
UA91546C2 (ru) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(b-D-ГЛЮКОПИРАНОЗ-1- ИЛ)-2-[4-((S)- ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ ПРИ ПРИГОТАВЛЕНИИ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
CA2620566A1 (en) | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
RU2008113050A (ru) | 2005-09-08 | 2009-10-20 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-(4-ЭТИНИЛБЕНЗИН)-БЕНЗОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ПРИГОТОВЛЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
US7745414B2 (en) | 2006-02-15 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
TWI370818B (en) | 2006-04-05 | 2012-08-21 | Astellas Pharma Inc | Cocrystal of c-glycoside derivative and l-proline |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
EP2019679B1 (en) | 2006-05-23 | 2018-06-20 | Theracos, Inc. | Glucose transport inhibitors and methods of use |
US7919598B2 (en) | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
DE102006031962A1 (de) | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
TWI403516B (zh) | 2006-07-27 | 2013-08-01 | Chugai Pharmaceutical Co Ltd | To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes |
US8039441B2 (en) | 2006-08-15 | 2011-10-18 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture |
US8283326B2 (en) | 2006-10-27 | 2012-10-09 | Boehringer Ingelheim International Gmbh | Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
JP2010508371A (ja) | 2006-11-06 | 2010-03-18 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル置換フェニル誘導体、該化合物を含有する医薬品及びその使用と製造方法 |
BRPI0718596B8 (pt) * | 2006-11-09 | 2021-05-25 | Boehringer Ingelheim Int | composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina |
UY30730A1 (es) | 2006-12-04 | 2008-07-03 | Mitsubishi Tanabe Pharma Corp | Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno |
TW200904405A (en) * | 2007-03-22 | 2009-02-01 | Bristol Myers Squibb Co | Pharmaceutical formulations containing an SGLT2 inhibitor |
BRPI0816258B8 (pt) | 2007-09-10 | 2022-12-27 | Mitsubishi Tanabe Pharma Corp | processo para a preparação de compostos úteis como inibidores de sglt |
MY152979A (en) | 2008-01-09 | 2014-12-15 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
BRPI0907119A2 (pt) | 2008-01-09 | 2015-07-14 | Sanofi Aventis Deutschland | Derivados de insulina tendo um perfil de ação de tempo extremamente retardado |
CN101503399B (zh) * | 2008-02-04 | 2012-06-27 | 白鹭医药技术(上海)有限公司 | C-芳基葡萄糖苷sglt2抑制剂 |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
EP2395968B1 (en) | 2009-02-13 | 2024-01-17 | Boehringer Ingelheim International GmbH | Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient |
NZ623838A (en) * | 2009-04-16 | 2015-09-25 | Taisho Pharmaceutical Co Ltd | Pharmaceutical compositions for the treatment of diabetes mellitus |
JP2012528170A (ja) * | 2009-05-27 | 2012-11-12 | ブリストル−マイヤーズ スクイブ カンパニー | 別の抗糖尿病薬を用いた先の治療に抵抗性を有する2型糖尿病患者をsglt2阻害剤およびその組成物を用いて治療する方法 |
WO2011120923A1 (en) * | 2010-03-30 | 2011-10-06 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof |
US20120283169A1 (en) * | 2010-11-08 | 2012-11-08 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
JP5876170B2 (ja) * | 2015-01-13 | 2016-03-02 | 株式会社平和 | 遊技機 |
-
2011
- 2011-11-02 US US13/287,216 patent/US20120283169A1/en not_active Abandoned
- 2011-11-07 KR KR1020137011966A patent/KR20130125365A/ko not_active Application Discontinuation
- 2011-11-07 JP JP2013537158A patent/JP2013541576A/ja active Pending
- 2011-11-07 NZ NZ608829A patent/NZ608829A/en unknown
- 2011-11-07 KR KR1020197034873A patent/KR102232451B1/ko active IP Right Grant
- 2011-11-07 CN CN201180064091XA patent/CN103282030A/zh active Pending
- 2011-11-07 WO PCT/EP2011/069532 patent/WO2012062698A1/en active Application Filing
- 2011-11-07 KR KR1020187022985A patent/KR102051285B1/ko active IP Right Grant
- 2011-11-07 EP EP11778916.4A patent/EP2637648A1/en not_active Withdrawn
- 2011-11-07 MX MX2013005095A patent/MX356491B/es active IP Right Grant
- 2011-11-07 CA CA2813661A patent/CA2813661C/en active Active
- 2011-11-07 AP AP2013006813A patent/AP2013006813A0/xx unknown
- 2011-11-07 AR ARP110104151A patent/AR083787A1/es unknown
- 2011-11-07 SG SG2013024849A patent/SG189249A1/en unknown
- 2011-11-07 CN CN201610579791.7A patent/CN106177957A/zh active Pending
- 2011-11-07 BR BR112013011968A patent/BR112013011968A2/pt not_active IP Right Cessation
- 2011-11-07 AU AU2011328231A patent/AU2011328231B2/en active Active
- 2011-11-07 EP EP19163940.0A patent/EP3539540A1/en active Pending
- 2011-11-07 EA EA201300550A patent/EA026712B1/ru not_active IP Right Cessation
- 2011-11-07 PE PE2013000955A patent/PE20140244A1/es not_active Application Discontinuation
-
2013
- 2013-04-07 IL IL225597A patent/IL225597A0/en unknown
- 2013-04-22 CL CL2013001104A patent/CL2013001104A1/es unknown
- 2013-05-02 MA MA35865A patent/MA34640B1/fr unknown
- 2013-05-08 CO CO13115446A patent/CO6781465A2/es not_active Application Discontinuation
- 2013-06-04 EC ECSP13012661 patent/ECSP13012661A/es unknown
-
2014
- 2014-01-17 US US14/157,678 patent/US20140256624A1/en not_active Abandoned
-
2015
- 2015-05-15 JP JP2015100121A patent/JP6141907B2/ja active Active
-
2017
- 2017-02-06 JP JP2017019822A patent/JP6515121B2/ja active Active
-
2018
- 2018-03-08 US US15/915,396 patent/US20180193427A1/en not_active Abandoned
- 2018-04-06 PH PH12018500767A patent/PH12018500767A1/en unknown
-
2020
- 2020-03-18 US US16/822,360 patent/US20200397867A1/en not_active Abandoned
-
2021
- 2021-08-12 US US17/400,221 patent/US20220152159A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
EA201101189A1 (ru) | Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии | |
EA201101187A1 (ru) | Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами | |
EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
MX356584B (es) | Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica. | |
EA200900940A1 (ru) | Фармацевтическая композиция, содержащая пиразол-о-глюкозидное производное | |
EA201170349A1 (ru) | Модуляторы mif | |
EA201290078A1 (ru) | Гетероциклические соединения для ингибирования pask | |
BR112013021236A8 (pt) | composto, composição,e, método de tratamento de um distúrbio, uma condição ou uma doença | |
EA201200793A1 (ru) | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин | |
EA200900896A1 (ru) | Соединения-агонисты гетероциклических рецепторов (варианты), фармацевтическая композиция на их основе, способ лечения диабета и метаболических расстройств, способ стимулирования выработки инсулина (варианты) и способы снижения уровня глюкозы и триглицеридов в крови посредством указанных соединений | |
MY152037A (en) | Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative | |
EA200801897A1 (ru) | Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений | |
MX2009009416A (es) | Derivados de bencimidazol y sus metodos de uso. | |
EA201101191A1 (ru) | Фармацевтическая композиция, включающая ингибитор sglt-2, ингибитор дпп-iv и необязательно другой антидиабетический агент, и ее применение | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
MX2009009417A (es) | Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor. | |
EA201000515A1 (ru) | Активаторы глюкокиназы | |
EA201101524A1 (ru) | Способ и композиция для лечения состояния, связанного с хемосенсорным рецептором | |
NO20091700L (no) | Florizinanaloger som inhibitorer av glukose-ko-transporter 2 | |
EA201200046A1 (ru) | Новые соединения, фармацевтическая композиция и связанные с ними способы | |
EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |